Vera Therapeutics Q2 net loss $20.2M, cash $181M; Phase 3 atacicept trial initiated

Vera Therapeutics, Inc.

2023-Q2 EPS reported -$1.23

Net loss of $20.2M ($0.46 per share) vs $14.9M ($0.55 per share) in Q2 2022.
Cash, cash equivalents, and marketable securities of $181.0M as of June 30, 2023; funds operations to early 2026.
Positive 36-week Phase 2b ORIGIN results: significant proteinuria reduction and eGFR stabilization.
Pivotal Phase 3 ORIGIN 3 trial for IgA nephropathy initiated in June 2023.
Preliminary ORIGIN 3 data expected in first half of 2025; additional Phase 2b data in H2 2023 and 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Vera Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income a net loss of $20.2 million, or $0.46 per share, EPS $0.46 per share.

Period: the second quarter ended June 30, 2023
Net income: a net loss of $20.2 million, or $0.46 per share
EPS: $0.46 per share
Result: reported results

Exact text from the filing

For the quarter ended June 30, 2023, the company reported a net loss of $20.2 million, or $0.46 per share, compared to a net loss of $14.9 million, or $0.55 per share, for the same period last year.

View on SEC.gov

16 earnings releases filed in the last 30 days. Browse all earnings releases →

Vera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040973

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.